What is Northland Capmk’s Estimate for HRTX Q1 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at Northland Capmk issued their Q1 2025 EPS estimates for Heron Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes expects that the biotechnology company will earn ($0.01) per share for the quarter. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Capmk also issued estimates for Heron Therapeutics’ Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS and Q4 2025 earnings at $0.01 EPS.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million.

Several other research analysts have also recently issued reports on HRTX. Needham & Company LLC reissued a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Friday. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Friday.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock opened at $2.24 on Monday. Heron Therapeutics has a one year low of $1.04 and a one year high of $3.93. The company has a market cap of $340.69 million, a P/E ratio of -12.44 and a beta of 1.60. The firm has a fifty day moving average of $1.70 and a two-hundred day moving average of $1.71.

Institutional Investors Weigh In On Heron Therapeutics

A number of large investors have recently added to or reduced their stakes in HRTX. Carolinas Wealth Consulting LLC lifted its holdings in shares of Heron Therapeutics by 49.4% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 41,356 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 13,669 shares in the last quarter. Two Sigma Advisers LP grew its holdings in Heron Therapeutics by 1.5% during the 4th quarter. Two Sigma Advisers LP now owns 823,871 shares of the biotechnology company’s stock valued at $1,261,000 after buying an additional 12,500 shares during the last quarter. State of Wyoming increased its position in Heron Therapeutics by 573.5% during the fourth quarter. State of Wyoming now owns 29,736 shares of the biotechnology company’s stock worth $45,000 after buying an additional 25,321 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Heron Therapeutics in the fourth quarter worth $1,071,000. Finally, Tang Capital Management LLC lifted its position in shares of Heron Therapeutics by 15.7% in the fourth quarter. Tang Capital Management LLC now owns 2,140,271 shares of the biotechnology company’s stock valued at $3,275,000 after acquiring an additional 290,271 shares in the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.